|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
2.4 Etiologie - Portables, ondes e-m
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
Air pollution tied to shorter survival with lung cancer [Reuters]
|
|
|
|
|
|
Researchers
examined cancer registry data on more than 350,000 people diagnosed
with lung cancer in California and found patients who lived in
communities with higher than average levels of air pollution typically
died sooner than their peers who lived in places with cleaner air.
|
|
|
|
|
|
|
3. Prévention
|
|
|
|
3.1 Tabac
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
Lilly breast cancer drug stumbles, but trial continues [Reuters]
|
|
|
|
|
|
The
independent data monitoring committee recommended the trial continue
without modification through the first half of 2017 despite the fact
that its interim look at the data suggested the combination treatment
was not delaying progression of the disease.
|
|
|
|
|
|
|
|
Elizabeth Warren demands open access to data from patient trials of drugs [STAT]
|
|
|
|
|
|
“I
appreciate that there are many policy, privacy, and practical issues
that need to be addressed in order to make data sharing practical and
useful for the research community,” Warren wrote in an editorial in the
venerable New England Journal of Medicine, “but the stakes are too high
to step back in the face of that challenge.”
|
|
|
|
|
|
|
Many pediatric clinical trials go unpublished or unfinished [STAT]
|
|
|
|
|
|
Specifically,
the researchers found that 19 percent of 559 randomized clinical
trials, or 104 studies, were discontinued. Of the 455 completed trials,
30 percent, or 136 studies, were not published, according to the study,
which was published Thursday in Pediatrics. More than 69,000 children
participated in those studies, by the way.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
A Painful Cancer Advertisement [In the Pipeline]
|
|
|
|
|
|
As
better therapies come along (and they’re coming along faster than usual
these days), this problem is going to occur more often. It’s going to
be increasingly painful to lose people to cancer when there are more
treatments and better treatments than in years past.
|
|
|
|
|
|
|
|
Immune System and Spirit Kept Cancer at Bay for a Year [NY Times]
|
|
|
|
|
|
I
recently chronicled the story of Jason Greenstein and his battle
against cancer. He was at the vanguard of a new kind of treatment that
unleashes the immune system to fight the disease as it does infections
caused by viruses and bacteria. But his reprieve lasted just over a
year.
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
Cancer drug companies cut prices to win NHS approval [The Guardian]
|
|
|
|
|
|
“Companies
are finding it possible to revise their value proposition – if I can
put it like that – enabling us to turn what would originally have been a
‘no’, which is why they were in the Cancer Drugs Fund, into a ‘yes’,”
said Nice’s chief executive, Sir Andrew Dillon.
|
|
|
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
|
|
6.8 Communication
|
|
|
Andrew McDonald: The war of words about cancer [BMJ Blogs]
|
|
|
|
|
|
To
me improving communication must start with addressing our use of
metaphor in discussions of disease and working towards professionals and
patients using a common language when they communicate. Let me
illustrate that last point by citing some terms often used by
oncologists when discussing cancer treatments with their patients.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
Imprecise research threatens precision medicine [STAT]
|
|
|
|
|
|
All
too often the science underpinning these targeted therapies has not
been up to snuff and the result has been greater uncertainty about
optimal treatment — just the opposite of what precision medicine intends
to do.
|
|
|
|
|
|
|
NEJM editorial doubles down on resistance to data sharing [STAT]
|
|
|
|
|
|
In
other words: Data sharing will cripple scientific progress and harm
patients. Full stop. Implicit in this bleak outlook is a rather stunning
arrogance. Are we really supposed to believe that only the researchers
who generate data are competent to analyze them?
|
|
|
|
|
|